VivoSeq
Immunology

Retinal Vasculitis

1

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Retinal Vasculitis is an early-stage landscape with 1 program across 1 company. The most active players are Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Aflibercept

Regeneron

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Protein / enzyme150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
Completed·Regeneron logoRegeneron·N/A·NCT06769412·550,000 enrolled
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
Unknown status·OOcular Immunology and Uveitis Foundation·Phase 4·NCT03066869·40 enrolled
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
Completed·Regeneron logoRegeneron·N/A·NCT07105228·290,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)